Can Medtronic (MDT) Stock Reach $105?

Key Takeaways

• The central target of $105 is the arithmetic mean of the verified analyst price targets that sit above the current share price, not a single firm's forecast or a published consensus.
• With Medtronic plc (MDT) trading near $92.77, reaching $105 would require a gain of roughly 13%, a substantial move for a large-cap medical device maker.
• Across 18 current analyst targets reviewed, the range spans $83 to $118, while the overall mean of all targets is about $100.
• Strong fiscal Q1 2027 results, raised guidance, and a nearly 3.2% dividend yield support the bullish case; valuation and slower second-half growth comparisons are the main concerns.
• Investors should watch the November earnings report, the MiniMed split-off, and any further analyst revisions.

Analyst Price Targets and Consensus View

Medtronic plc is a diversified medical device company listed on the NYSE. Roughly 27 to 30 analysts cover the stock, and the broader consensus is a "Moderate Buy" with no Sell ratings currently recorded.

Because the average of all current targets sits only slightly above the share price, the $105 central target here is calculated as the mean of the verified targets that exceed the current price. The 18 targets reviewed range from a low of $83 at Goldman Sachs to a high of $118 at RBC Capital, while the average of all 18 is approximately $100. Recent revisions cluster between roughly $95 and $118.

Views differ by theme. Bulls, including TD Cowen, UBS, and Bank of America, point to accelerating growth in cardiac ablation, robotics, and renal denervation. More cautious analysts, such as Piper Sandler ($85) and J.P. Morgan ($86), argue the shares already reflect much of the near-term improvement. UBS upgraded Medtronic to Buy in July and raised its target to $110 in September, while Barclays initiated coverage at Hold with a $95 target in October.

Current Market Position and Path Toward the Target

Medtronic shares closed near $92.77, leaving a roughly 13% gap to the $105 central target. The stock has swung widely over the past year, trading from the low $70s to above $100, and now sits well off its peak after recovering from a mid-2026 trough.

Fundamentally, Medtronic reported fiscal Q1 2027 results in early September, with revenue of $9.76 billion up 13.7% year over year and adjusted EPS (earnings per share) of $1.45, ahead of the $1.39 consensus. The quarter included an extra selling week worth roughly $570 million. Management raised its full-year organic revenue growth outlook to 7.25% to 7.75% and its adjusted EPS guidance to $5.94 to $6.00.

What Could Support a Move Toward the Target

• Broad-based momentum across cardiovascular, neuroscience, and surgical segments, led by cardiac ablation solutions and the Hugo robotics platform.
• Raised full-year guidance and a pipeline of new procedure codes for the Altaviva and Symplicity Spyral technologies.
• A dividend yielding roughly 3.2%, with the company one increase away from Dividend King status (50 consecutive years).
• A forward P/E (price-to-earnings ratio) in the mid-teens that represents a discount to several large-cap medtech peers.
• Continued analyst upgrades and target increases through the summer and fall of 2026.

What Could Prevent the Target From Being Reached

• The extra selling week flatters headline growth; underlying comparisons become harder in the next quarter.
• Slower-than-expected adoption of Hugo robotics or new therapies could weigh on sentiment.
• The MiniMed Group split-off adds execution risk and temporarily reshapes reported results.
• If growth slows back toward the mid-single digits seen earlier in fiscal 2026, valuation multiples could compress.
• Several analysts hold targets below the current price, signaling that downside scenarios remain part of the debate.

Technical Levels and Market Structure

The shares have recovered from a 52-week low in the low $70s but face resistance near the psychologically important $100 level and the 52-week high around $106. A sustained move above $100 would be a key step toward the $105 target, while the recent recovery zone in the $85-to-$90 area represents a nearby support level.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month horizon, though individual firms use different frameworks. The next earnings report is expected in mid-November 2026, and revenue growth relative to the 13.7% pace from fiscal Q1 is the key number to watch. Investors should also monitor the completion of the MiniMed split-off, updates on the new procedure codes taking effect in January 2028, and any further analyst revisions or target changes.

AI Daily Buy/Sell Signals

Beyond fundamental research, traders increasingly turn to automated tools to track shifting conditions. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The platform is designed to help traders discover opportunities, monitor existing positions, and spot emerging trends more efficiently than manual screening alone. Explore the AI Daily Buy/Sell Signals to see how AI-driven insights can complement your own research.

Final Assessment

The question of whether Medtronic (MDT) can reach $105 is really a question about whether the company's growth acceleration is durable. The central target, an average of analyst targets above the current price, sits roughly 13% higher than the latest quote and is backed by strong recent results, raised guidance, and improving analyst sentiment. At the same time, the wide $83-to-$118 target range reflects genuine disagreement over whether the reacceleration can be sustained, and meaningful resistance near $100 must be cleared first. With earnings due in November, the next update will be a critical test of the path toward $105.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations